Takotsubo cardiomyopathy was first described in 1990 in Japan [@bib0005], and is characterized by: (1) transient left ventricular wall motion abnormalities in the left ventricular mid segments with or without apical involvement; (2) the absence of obstructive coronary disease or angiographic evidence of acute plaque rupture; (3) electrocardiographic changes that mimic acute myocardial infarction in spite of minimal release of myocardial enzymes; and (4) the absence of pheochromocytoma and myocarditis [@bib0010]. Given the transient nature of this syndrome and its complete resolution, the prognosis of patients with takotsubo cardiomyopathy is generally favorable [@bib0015], [@bib0020], [@bib0025]. However, it is important to pay attention to the hemodynamics of patients with takotsubo cardiomyopathy in the acute phase, because heart failure is the most common clinical complication and some fatal complications such as left ventricular free wall rupture were also reported [@bib0015]. The precise etiology and pathophysiology of this syndrome remain unknown, and the treatment of this syndrome is usually empirical and individualized according to the patient\'s characteristics at the time of presentation.

Because the onset of takotsubo cardiomyopathy is often preceded by emotional or physical stress, abnormal catecholamine dynamics related to emotional distress seem to play a major role in the pathogenesis of takotsubo cardiomyopathy, and several mechanisms have been proposed to explain the unusual features of this syndrome, such as catecholamine-mediated multivessel epicardial spasm [@bib0030], microvascular coronary spasm [@bib0035], or direct catecholamine-mediated myocyte injury [@bib0040]. In addition, it was reported that drugs with sympathetic effects could also precipitate takotsubo cardiomyopathy [@bib0045], and drug-induced takotsubo cardiomyopathy needs be considered in patients suffering from this disease without any apparent emotional or stress trigger.

A case report by Sasaki et al. [@bib0050] in this issue of *Journal of Cardiology Cases* describes a case of a 65-year-old woman who suffered from takotsubo cardiomyopathy and concomitant serotonin syndrome due to interaction of an anti-depressant agent (maprotiline) and an antitussive agent (dextromethorphan). After discontinuation of these agents and appropriate treatment for serotonin syndrome under mechanical supportive care, the patient could be discharged well. Although the mechanistic link between takotsubo cardiomyopathy and serotonin syndrome remains to be clarified, Sasaki et al. suggest in their case report [@bib0050] that serotonin syndrome resulted in a hyperserotonergic and hyperadrenergic state, leading to the onset of takotsubo cardiomyopathy. Because drugs that may contribute to serotonin syndrome including anti-depressant agents are now under widespread use in clinics, this case emphasized the need for clinicians to recognize serotonin syndrome as a trigger of drug-induced takotsubo cardiomyopathy.

Serotonin syndrome is a potentially life-threatening condition caused by excessive serotonergic activity in the nervous system. A striking number of drugs and drug combinations have been associated with the serotonin syndrome. It was also reported that the incidence of serotonin syndrome is rising, reflecting the growing number of serotonergic drugs available and the increased use of these agents in clinical practice [@bib0055]. Because there are no specific laboratory tests that allow clinicians to diagnose this syndrome, the diagnosis depends on the presence of a clinical triad of mental-status changes, autonomic instability, and neuromuscular hyperactivity [@bib0055], [@bib0060], and is made primarily on the basis of the Hunter Serotonin Toxicity Criteria [@bib0065]. Diagnosis of serotonin syndrome with Hunter\'s criteria requires the presence of one of the following classical features or groups of features: spontaneous clonus; inducible clonus with agitation or diaphoresis; ocular clonus with agitation or diaphoresis; tremor and hyperreflexia; or hypertonia, temperature above 38 °C, and ocular or inducible clonus. Although the serotonin syndrome appears to occur in a broad range of clinical environments, it is not always easy to diagnose this syndrome due to its protean manifestations, and many of the mild cases may be overlooked. Moreover, the onset of symptoms is usually rapid: it was reported that about 60% of patients with the serotonin syndrome present within 6--24 h after a medication change or overdose [@bib0070]. It should be noted that serotonin syndrome does not resolve spontaneously as long as precipitating agents continue to be administered, and an inadvertent increase in the dose of the causative agent or the addition of a drug with proserotonergic effects may provoke a dramatic clinical deterioration, and severe cases may rapidly progress to death [@bib0055], [@bib0060]. Therefore, management of the serotonin syndrome involves the removal of the causative drugs, the provision of supportive care, the administration of serotonin antagonists, and the control of agitation, autonomic instability, and hyperthermia.

Although both serotonin syndrome and takotsubo cardiomyopathy can be fatal, the prognosis of these diseases is generally favorable when managed appropriately. Clinicians should be aware of the existence and the typical clinical manifestations of serotonin syndrome, and serotonin syndrome should be considered as a possible cause of drug-induced takotsubo cardiomyopathy.
